Brief: Cytodyn Reports Strong Positive Preclinical Data To Demonstrate Potential Of Leronlimab
21/11/2019 12:16
Nov 21 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN REPORTS STRONG POSITIVE PRECLINICAL DATA TO
DEMONSTRATE
POTENTIAL OF LERONLIMAB IN TREATING NONALCOHOLIC FATTY LIVER
DISEASE (NAFLD) IN HUMANIZED MOUSE MODEL
Source text for Eikon: ID:nGNX5x7yFl
Further company coverage: CYDY.PK
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer